JP2025511847A - ラニフィブラノールの結晶形態 - Google Patents

ラニフィブラノールの結晶形態 Download PDF

Info

Publication number
JP2025511847A
JP2025511847A JP2024559386A JP2024559386A JP2025511847A JP 2025511847 A JP2025511847 A JP 2025511847A JP 2024559386 A JP2024559386 A JP 2024559386A JP 2024559386 A JP2024559386 A JP 2024559386A JP 2025511847 A JP2025511847 A JP 2025511847A
Authority
JP
Japan
Prior art keywords
lanifibranor
crystalline form
pxrd
curve
pxrd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511847A5 (https=
Inventor
フレデリック ベル，
ベナイサ ブービア，
Original Assignee
インベンティバ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンティバ filed Critical インベンティバ
Publication of JP2025511847A publication Critical patent/JP2025511847A/ja
Publication of JP2025511847A5 publication Critical patent/JP2025511847A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024559386A 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態 Pending JP2025511847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305456.0 2022-04-05
EP22305456 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (2)

Publication Number Publication Date
JP2025511847A true JP2025511847A (ja) 2025-04-16
JP2025511847A5 JP2025511847A5 (https=) 2026-04-08

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559386A Pending JP2025511847A (ja) 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態

Country Status (14)

Country Link
US (1) US20250243192A1 (https=)
EP (1) EP4504725A1 (https=)
JP (1) JP2025511847A (https=)
KR (1) KR20250002337A (https=)
CN (1) CN119301120A (https=)
AR (1) AR128985A1 (https=)
AU (1) AU2023250118A1 (https=)
CA (1) CA3247273A1 (https=)
IL (1) IL316075A (https=)
MX (1) MX2024012348A (https=)
PY (1) PY2324870A (https=)
TW (1) TW202404966A (https=)
UY (1) UY40216A (https=)
WO (1) WO2023194339A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240343723A1 (en) * 2021-08-12 2024-10-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of lanifibranor, preparation method therefor, and use thereof
AU2024208998A1 (en) 2023-01-19 2025-08-21 Inventiva Lanifibranor formulation
IL325022A (en) 2023-06-05 2026-01-01 Inventiva Nifibranor for use in the treatment of splenic vasodilation in a patient with liver disease
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
WO2025132989A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025132955A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
TW202543596A (zh) 2024-03-15 2025-11-16 法商因文帝華公司 預防接受過氧化物酶體增生劑活化受體（ppar）促效劑治療患者之血液病症
WO2025238200A1 (en) 2024-05-17 2025-11-20 Inventiva Treatment of a liver disease in patients with hepatic impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
US20240343723A1 (en) 2021-08-12 2024-10-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
US20250243192A1 (en) 2025-07-31
UY40216A (es) 2023-10-31
IL316075A (en) 2024-12-01
AR128985A1 (es) 2024-07-03
AU2023250118A1 (en) 2024-10-17
EP4504725A1 (en) 2025-02-12
KR20250002337A (ko) 2025-01-07
MX2024012348A (es) 2024-11-08
CN119301120A (zh) 2025-01-10
PY2324870A (es) 2023-10-27
TW202404966A (zh) 2024-02-01
CA3247273A1 (en) 2023-10-12
WO2023194339A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JP2025511847A (ja) ラニフィブラノールの結晶形態
EP1720853B1 (en) Novel polymorphic form of imatinib mesylate and a process for its preparation
JP7199739B2 (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
KR20160118204A (ko) 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
JP2020519654A (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
CN111479798B (zh) 三亚乙基四胺四盐酸盐的晶形及其医药用途
US9856270B2 (en) Dolutegravir salts
HUE026408T2 (en) Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
HUE026726T2 (en) Crystalline naloxol-PEG conjugate
JP5875863B2 (ja) マレイン酸オルブピタントの無水結晶形
EP3173400A1 (de) Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR20200138283A (ko) 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
EA052550B1 (ru) Кристаллическая форма ланифибранора
WO2022136335A1 (en) Forms of linerixibat
HK40120719A (zh) 拉尼兰诺的晶型
EP3587421A1 (en) Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
CN106478616B (zh) 一种gpr40激动剂的结晶形式及其制备方法
HUE027309T2 (en) Crystalline solvates of 6- (Piperidin-4-ylix) -2H-isoquinolin-1-one hydrochloride
US20260109685A1 (en) Solid forms of pralsetinib
WO2018172950A1 (en) Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
WO2026074067A1 (en) Solid forms of a gamma-secretase modulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260327